# US 2010/0247524 A9 · Methods for treating Chronic Obstructive Pulmonary Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0247524 A9
- Document ID: US20100247524A9
- Status: Published application
- Kind: A9
- Application number: 11/917,572
- Filed: 2006-06-30
- Published: 2010-09-30
- Earliest claimed: 2005-06-30
- Inventors: Clifford G. Risk
- Web page: https://patentgrep.com/patent/US20100247524A9

## CPC

- C07K 16/4291: {against IgE}
- A61K 39/39566: {against immunoglobulins, e.g. anti-idiotypic antibodies}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y10S 424/805: involving IgE or IgD
- Y10S 424/81: involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
- Y10S 530/862: involving IgE or IgD
- Y10S 530/868: involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, COFD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, to be useful ioÊ the treatment of COPD patients regardless of their skin test results arid/or in vitro reactivity to a perennial aeroalleigen. Anti-EgE moieties, in accordance With the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal iirunuitoglobulln E (e.g., human imntnnoglQbulin E) such as humanized arrti-IgEy hmuanized murine monoclonal antibody, and/or Qmalizumab.

## Claims

### Claim 1

A method of treating a mammal having COPD comprising administering said mammal a therapeutically effective amount of an anti-IgE moiety to the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the anti-IgE moiety is a humanized IgG antibody that selectively hinds to human immunoglobulin E.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the humanized IgG antibody that selectively hinds to human immunoglobulin E is a murine monoclonal antibody.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the anti-IgE moiety is Omalizumab.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the mammal has an elevated serum IgE level.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the mammal has a negative skin test.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the mammal has a negative in vitro reactivity to a perennial aeroallergen.
